drugset / Trial / NCT02598388

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

NCT02598388

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to assess the safety, tolerability and immunogenicity of different vaccination schedules of Ad26.ZEBOV and MVA-BN-Filo administered intramuscularly (IM) as 2-dose heterologous regimens in healthy and in HIV-infected adults.

Timeline

Start
2015-12-10
Primary completion
2018-12-12
Completion
2018-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN Vaccine 0.5 ml Intramuscular
Subject MVA-BN-Filo Vaccine 0.5 ml Intramuscular